Published Review and Analyst Report Boost TapImmune Inc. Shares

NEW YORK, NY--(Marketwired - November 18, 2014) - TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.

Dr. Wilson, in an exclusive interview with Life Sciences Intellectual Property Review, estimates the Seattle-based company will be worth more than $1 billion in just five years.

The U.K. Based Life Sciences Intellectual Property Review tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.

Dirks Research, in a separate report released on Monday, said that an official announcement regarding the start of Phase II clinical trials for TapImmune's immunotherapy cancer vaccines for Breast and Ovarian cancer is imminent.

Analysts also noted that a push of the company's development pipeline into Phase II for two urgently needed therapeutic indications, each with blockbuster potential and huge market opportunities simultaneously, would likely create an inflection point in prices and valuation for the Seattle based firm.

In a recent quarterly filing, officials at TapImmune indicated that they planned to initiate the two pending Phase II studies in Q4 of 2014.

About BioMedReports

BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. Full disclosures and information about the stocks and information mentioned in this news release are available at BioMedReports.Com

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at for details.

Media Contacts Only:
M. Davila
Assistant Editor
e-mail: Email Contact

Help employers find you! Check out all the jobs and post your resume.

Back to news